About The Angels’ Forum
The Angels’ Forum is a venture capital firm founded in 1997. It is primarily based out of Mountain View, United States. As of Jul 2020, The Angels’ Forum has invested in 59 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Enterprise Applications to Life Sciences and Retail. Most recently it participated in the $***** Series C round of Vida Lung Overall, The Angels’ Forum portfolio has seen 2 IPOs and 21 acquisitions including key companies like Sonos, Taulia and Citrix. A lot of funds co-invest with The Angels’ Forum, with names like The Halo Fund sharing a substantial percentage of its portfolio. The Angels’ Forum has team of 9 people including 7 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio Soonicorns
The Angels’ Forum's List of Top Investments
The Angels’ Forum has a portfolio of 59 companies. Their most notable investments are in Taulia and Halio.Their portfolio spans across United States, Israel and Spain. They have invested in Enterprise Applications, Life Sciences, Retail and 22 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by The Angels’ Forum:1. Sonos
Manufacturer of wireless speakers, home sound systems, and audio components. The company designs speakers with acoustics and software. It offers products for creating sound systems, pairing speakers, and building surround sound systems. The company provides an application for setup and control of audio streaming.
Key facts about Sonos
- Founded Year: 2002
- Location: Santa Barbara (United States)
- Annual Revenue: $1B+ as on Sep 30, 2025
- Stage: Public
- Total Funding till date: $296M
- Employee Count: 1,840 as on May 31, 2026
- Investors: eversourcecap.com, Floodgate and 12 Others
- Latest Funding Round: Series E, Dec 02, 2014, $*****
- Highlight: Public
2. Taulia
AI-based electronic invoicing and supply chain management solution for businesses. It features solutions to provide dynamic discounting, supply chain finance, cash forecasting, invoice automation, supplier management, and more. It offers a web-based invoice management solution that allows you to choose an early payment option using their working capital or third-party funds.
Key facts about Taulia
- Founded Year: 2009
- Location: San Francisco (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $220M
- Employee Count: 190 as on May 31, 2026
- Investors: Questmark Capital Management, Harmonic and 26 Others
- Latest Funding Round: Conventional Debt, Mar 11, 2021, $*****
- Highlight: Acquired
3. Citrix
Provider of secure application delivery and desktop virtualization platform solutions. The platform centralizes application and desktop management for distributed workforces. It delivers mission critical applications and protects sensitive business information. The platform also powers sustainable business IT and manages onboarding and offboarding.
Key facts about Citrix
- Founded Year: 1989
- Location: Fort Lauderdale (United States)
- Annual Revenue: $1B+ as on Dec 31, 2021
- Last Known Valuation: $*****
- Stage: Acquired
- Employee Count: 4,226 as on Mar 31, 2026
- Investors: Elliott Management, Intel and 15 Others
- Latest Funding Round: Grant (prize money), Nov 01, 2019, $*****
- Highlight: Acquired
4. Mission Bio
Provider of a single-cell multi-omics platform for genotypic and phenotypic analysis. The company's proprietary Tapestri platform enables the simultaneous detection of analytes, including SNVs, CNVs, and proteins for the precise treatment of cancer. Also, it offers DNA & protein panels, and Pharma Assay Development (PAD) Services.
Key facts about Mission Bio
- Founded Year: 2014
- Location: San Francisco (United States)
- Stage: Series C
- Total Funding till date: $120M
- Employee Count: 88 as on May 31, 2026
- Investors: Novo Holdings, Soleus Capital and 29 Others
- Latest Funding Round: Series C, Aug 05, 2025, $*****
- Highlight: Editors' Pick
5. Penumbra
Developer of medical devices for neurovascular and peripheral thrombectomy. The company manufactures and supplies catheters, aspiration pumps, and related equipment used in minimally invasive procedures to treat stroke and other vascular occlusions. These devices are designed to remove blood clots, restoring blood flow to affected areas. The company also provides clinical evidence and resources to support healthcare providers using its technology. Its product line includes systems for both neurovascular and peripheral applications.
Key facts about Penumbra
- Founded Year: 2004
- Location: Alameda (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Acquired
- Total Funding till date: $121K
- Employee Count: 3,123 as on May 31, 2026
- Investors: Novo Holdings, The Angels’ Forum and 4 Others
- Latest Funding Round: Post IPO, May 28, 2020, $*****
- Highlight: Acquired
The Angels’ Forum's Year-on-Year Investment Trends
The Angels’ Forum has invested in 59 companies over the last 23 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in Vida Lung and most recent follow-on round was in RenovoRx.The Angels’ Forum's Investments by Stage
The Angels’ Forum has made 7 investments in Series A stage with an average round size of $3.52M, 3 investments in Series B stage with an average round size of $8.38M and 2 investments in Seed stage with an average round size of $2.15M.Stage of entry | No. of Investments |
|---|---|
Series A | 7 |
Series B | 3 |
Seed | 2 |
Series C | 2 |
Series D | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
The Angels’ Forum's Investments by Sector
The Angels’ Forum has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, High Tech, Retail and Sustainability Tech. Notably, it has invested in 47 Tech companies, 42 Enterprise (B2B) companies, 32 Software companies and at least 17 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
Enterprise Applications | 7 |
High Tech | 3 |
Retail | 2 |
Sustainability Tech | 2 |
Others | 15 |
Note: We have considered here, only first round of investments
The Angels’ Forum's Investments by Geography
The Angels’ Forum has made most investments in United States (18).The Angels’ Forum's recent investments
The Angels’ Forum has not made any investment in 2026 so far.Here are the most recent investments by The Angels’ Forum:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 03, 2020 | United States | Series C | 3377 | [+7] | |
May 23, 2018 | United States | Series D | 8950 | [+5] | |
2017 | United States | Series A | 8497 | - | |
Jul 04, 2017 | United States | Series C | 7256 | - | |
Sep 10, 2014 | United States | Seed | 3093 | [+2] |
IPOs and Publicly Listed companies in The Angels’ Forum's Portfolio
2 of The Angels’ Forum's portfolio companies have become public. RenovoRx got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2021 at marketcap of $75.5M and Sonos got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $208M.Here are The Angels’ Forum's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 26, 2021 | Jan 28, 2014 | Series B | 3420 | |
Aug 02, 2018 | - | - | 1617 |
Acquired companies in The Angels’ Forum's Portfolio
21 companies from The Angels’ Forum's portfolio have been acquired. The most recent acquisition was Penumbra in Jan 2026 by Boston Scientific for $*****.Here are The Angels’ Forum's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 15, 2026 | - | - | 8478 | |
Jan 08, 2025 | - | - | 9781 | |
Dec 19, 2022 | Jul 21, 2008 | Post IPO | 9302 | |
Aug 30, 2022 | - | - | 4641 | |
Jan 31, 2022 | - | - | 3693 |
Team profile of The Angels’ Forum
The Angels’ Forum has a team of 9 members including 7 Partners and 1 Principal located in United States. The Angels’ Forum's team does not sit on the board of any company as of now.Here is a list of all team members in The Angels’ Forum:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | - | |
Partner | San Francisco | - | - | |
Partner | San Francisco | - | - | |
Partner | Palo Alto | - | ||
Partner | Saratoga | - | - | |
Partner | San Francisco | - | - | |
Partner | San Jose | - | - | |
Principal | Mountain View | - | - |
Co-investors of The Angels’ Forum
Over the past 23 years, 107 investors have co-invested in The Angels’ Forum's portfolio companies. This includes funds and angels.
- Invested before The Angels’ Forum: HHS, National Science Foundation and 23 others have invested in rounds before The Angels’ Forum. There are 2 companies where HHS has invested before The Angels’ Forum and 1 company where National Science Foundation has invested before The Angels’ Forum.
- Top Co-investors of The Angels’ Forum: 39 investors entered a company along with The Angels’ Forum. These include investors like The Halo Fund (6 companies).
- Invested after The Angels’ Forum: A total of 43 investors have invested in The Angels’ Forum's portfolio after their investments. Top Investors include DAG Ventures (1 company), QuestMark Partners (1 company) and Lakestar (1 company).
Recent News related to The Angels’ Forum
•
•
RenovoRx Announces $10 Million Financing for Innovative Treatment for Advanced Pancreatic CancerBusiness Wire•May 23, 2018•RenovoRx, Boston Scientific, BtoV, Astia and 4 others
•
Stanford StartX & Mission Bay Capital Invest $1.86M in U.C. Berkeley Spin-out for Single Cell Analysis | Business WireBusiness Wire•Sep 10, 2014•Zephyrus Biosciences, NIH, Life Science Angels, Mission Bay Capital and 2 others
•
Gemmus Pharma Closes $3.3M Series B Funding to Develop Superior Flu Drug | Business WireBusiness Wire•May 13, 2014•Gemmus Pharma, Life Science Angels, BlueTreeVC, Tech Coast Angels and 2 others
•
Gemmus Pharma Closes $3.3M Series B Funding to Develop Superior Flu Drug | Business WireBusiness Wire•May 13, 2014•Gemmus Pharma, Life Science Angels, BlueTreeVC, Tech Coast Angels and 2 others
•
•
Bella Pictures takes $10.3M for wedding photography | VentureBeatVentureBeat•Dec 18, 2009•Bella Pictures, The Angels’ Forum, Foundation Capital, TPG
•
Qumu raises $10.7M for enterprise videoVentureBeat•Jul 21, 2008•Qumu, Advanced Technology Ventures, Storm Ventures, Garage Technology Ventures and 3 others
•
Record Labels Strategically Invest $2.8M in MOG – TechCrunchTechCrunch+•Apr 29, 2008•MOG, The Angels’ Forum, Universal Music Group
•
